At Nightstar, our mission is to maintain and restore sight in patients with inherited retinal diseases.
We are a clinical-stage company focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and, for which, there are no currently approved treatments.Read More
Copyright Nasdaq. Minimum 15 minutes delayed.
September 27, 2017